Potassium%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an essential electrolyte used to prevent or treat hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. ## Adult Dosing * **Oral:** * Prevention: 20 mEq (1.5 g KCl) daily. * Treatment: 40-100 mEq (3-7.5 g KCl) daily in divided doses. Maximum daily dose generally 120-200 mEq (9-15 g KCl), depending on severity and clinical assessment. Some sources suggest a maximum of 20 mEq per dose for extended-release preparations to minimize gastrointestinal intolerance. * **Intravenous (IV):** * Treatment of hypokalemia: Dosing is highly individualized based on serum potassium level, clinical status, and EKG findings. * Common initial doses range from 10 mEq to 40 mEq. * Maximum infusion rates are crucial to prevent cardiac arrhythmias: * Peripheral IV: Typically no faster than 10 mEq/hour. * Central IV: Can be infused up to 20 mEq/hour in severe, symptomatic hypokalemia with continuous cardiac monitoring. Rates >20 mEq/hour are rarely used and require extreme caution and intensive monitoring. * Maximum concentration: Peripheral IV: 40 mEq/L. Central IV: up to 100 mEq/L, but often limited to 80 mEq/L. ## Pediatric Dosing * **Oral:** * Maintenance: 2-3 mEq/kg/day divided in 2-4 doses. Maximum daily dose typically 100 mEq. * **Intravenous (IV):** * Dosing is highly individualized based on serum potassium, weight, and clinical status. * A common guideline for severe hypokalemia is 0.5-1 mEq/kg/dose, infused over 1-3 hours, not to exceed 10 mEq/hour and 40 mEq per dose (unless in a central line with cardiac monitoring). * Maximum daily dose should not exceed 100 mEq or maintenance requirements. * Concentrations and infusion rates are critical and should generally not exceed 40 mEq/L and 10 mEq/hour peripherally. Central line administration may allow higher concentrations (up to 80 mEq/L) and rates (up to 20 mEq/hour) with appropriate monitoring. ## Dose Adjustments * **Renal Impairment:** Dose reduction is necessary. Monitor potassium levels closely. Use with extreme caution or avoid in severe renal impairment. ## Contraindications * Hyperkalemia. * Conditions leading to increased potassium levels (e.g., severe renal impairment, untreated Addison's disease, acute dehydration, extensive tissue breakdown). * Certain medications that can cause hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, ARBs, NSAIDs) should be used with extreme caution. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain (especially with oral formulations). * **Serious:** Hyperkalemia (manifesting as fatigue, weakness, paresthesias, confusion, cardiac arrhythmias, cardiac arrest), gastrointestinal bleeding or perforation (especially with sustained-release oral forms). ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene), ACE inhibitors, ARBs, NSAIDs, heparin, trimethoprim:** Increased risk of hyperkalemia. Concurrent use requires close monitoring of serum potassium. * **Aliskiren:** Increased risk of hyperkalemia. * **Certain salt substitutes:** Contain large amounts of potassium chloride and can contribute to hyperkalemia if used excessively. * **Insulin and Beta-2 Agonists:** Can lower serum potassium by shifting potassium intracellularly; may mask developing hypokalemia. ## Monitoring * Serum potassium levels (frequency depends on route, dose, clinical status, and renal function). * Renal function (BUN, creatinine). * EKG for signs of hyperkalemia (peaked T waves, prolonged QRS, loss of P waves). * Monitor for signs and symptoms of hypokalemia (muscle cramps, weakness, fatigue, constipation, arrhythmias) and hyperkalemia (as listed under Adverse Effects). ## Clinical Pearls * Oral potassium supplements can cause gastrointestinal irritation. Advise patients to take with food or a full glass of water. * Sustained-release formulations may be better tolerated but still carry a risk of gastrointestinal issues. * IV potassium administration must be done with caution due to the risk of cardiac toxicity. **Never administer as an IV bolus.** * Hypokalemia can be exacerbated by magnesium deficiency; consider assessing and correcting magnesium levels. * Correcting hypokalemia in patients taking digitalis glycosides is crucial to prevent digitalis toxicity. *** *This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and recommendations may vary based on individual patient factors and local protocols.*